UPDATE: Jefferies Raises PT on Biogen Idec on FDA Tecfidera Approval
March 28, 2013 at 10:26 AM EDT
In a report published Thursday, Jefferies analyst reiterated a Buy rating on Biogen Idec (NASDAQ: BIIB ), and raised the price target from $201.00 to $215.00. In the report, “In line with expectations, the FDA approved Tecfidera (BG12) for multiple sclerosis. The label was better than we had expected, with
